Key Timeline at a Glance
| Date or Period | Event | Why It Matters |
|---|---|---|
| February 2013 | Angelina Jolie underwent a preventive double mastectomy | Elective surgery to markedly reduce high cancer risk based on BRCA1 mutation |
| May 2013 | Jolie published op-ed in The New York Times | Explained her medical decision and family context |
| Age at surgery | 37 years old | Context for why a preventive approach was chosen relatively early |
Angelina Jolie Mastectomy: Core Facts
In February 2013, actor and filmmaker Angelina Jolie, then 37, elected to undergo a preventive double mastectomy. The decision was driven by a inherited mutation in the BRCA1 gene, which substantially elevated her lifetime risk of breast cancer. In a widely read New York Times op-ed published in May 2013, Jolie explained that the surgery reduced her risk of developing breast cancer by approximately 80–90 percent. The procedure was not a response to a cancer diagnosis but a risk-reducing (prophylactic) measure taken to protect her health and limit the possibility of future cancer.
Medical Rationale and Inherited Risk
BRCA1 Mutation and Elevated Cancer Risk
Mutations in BRCA1 and BRCA2 genes are associated with a significantly higher lifetime risk of breast and ovarian cancers. For people with a harmful BRCA1 mutation, the estimated lifetime risk of breast cancer is roughly 55–70 percent, compared with about 12 percent in the general population. Jolie’s mother died of ovarian cancer at age 56, and multiple family members had breast cancer, leading to heightened concern about inherited risk. Genetic testing confirmed a BRCA1 mutation, a key factor in her decision to pursue preventive mastectomy.
Why a Preventive Mastectomy Was Chosen
For individuals with very high genetic risk, risk-reducing mastectomy can substantially lower the likelihood of developing breast cancer. Studies suggest that prophylactic mastectomy is linked with a large relative risk reduction—often cited as 80–90 percent for breast cancer incidence. For Jolie, the goal was to retain as much of her natural anatomy as possible while avoiding the trauma of a cancer diagnosis and more extensive treatment later. She also opted for a separate oophorectomy (removal of the ovaries and fallopian tubes) several years later to further reduce ovarian cancer risk, typically recommended in the early 40s for BRCA1 carriers.
Context and Decision-Making Process
Family History and Genetic Counseling
Jolie’s decision was shaped by a multi-step process that included consulting with doctors, genetic counselors, and reviewing her family’s cancer history. The presence of BRCA1 mutations in some family members, combined with her mother’s early cancer death, made her long-term risk unusually high. Genetic counseling helps individuals understand probability estimates, limitations of current knowledge, and options—such as enhanced screening, chemoprevention, or surgery—and Jolie chose the surgical route.
Media Disclosure and Public Conversation
In May 2013, Jolie wrote a candid op-ed describing her experience, the data she reviewed, and the emotional factors involved. Her disclosure helped frame public understanding of preventive surgery and highlighted the importance of access to genetic testing and informed choice. She made clear that not every woman with a BRCA mutation needs mastectomy, but for some with especially high risk, it can be a life-saving option.
Age at Surgery and Why It Matters
Angelina Jolie was 37 years old at the time of her preventive mastectomy in 2013. Undergoing major surgery at this age is uncommon for purely preventive reasons and reflects the urgency often seen in people with very high genetic risk. Earlier intervention can be considered when cancer risk is substantial and long-term protection is the goal; operating at a younger age also allows for planned reconstruction and, when desired, future discussions about fertility and family planning. The decision was made before any cancer diagnosis, distinguishing it from therapeutic mastectomy performed after a malignancy is found.
Broader Implications and Public Health Context
Impact on Awareness and Access
Jolie’s public discussion of her preventive mastectomy increased awareness about hereditary cancer risk, genetic testing, and proactive health management. It also underscored disparities in access to care—genetic testing, specialist consultation, and reconstructive surgery are not equally available worldwide. Public dialogue helped normalize conversations about hereditary cancer and the variety of risk-management strategies available, from intensified surveillance to preventive surgery and chemoprevention.
Comparison of Options for High Genetic Risk
- Enhanced screening (earlier and more frequent mammography/MRI) — may detect cancer earlier but does not prevent it.
- Risk-reducing medications (chemoprevention) — can lower risk but may have side effects and is not as effective as surgery for risk reduction.
- Risk-reducing mastectomy — substantially lowers breast cancer risk but is irreversible and involves surgical and reconstructive considerations.
- Risk-reducing salpingo-oophorectomy — recommended for BRCA carriers to reduce ovarian cancer risk, typically in the late 30s to early 40s.
Addressing Common Misunderstandings
Some assume that Jolie’s situation applies broadly to all women with a family history of cancer. In reality, recommendations are individualized based on the specific mutation, family history, age, and personal preferences. Most people with a family history of cancer do not carry a high-penetrance BRCA mutation, and many options exist to manage risk without mastectomy. Jolie’s case is notable because her estimated risk was high enough that prophylactic mastectomy provided a meaningful mortality benefit, but such decisions require careful medical evaluation and genetic counseling.